Regulatory Science & Clinical Research: Where Do We Stand (And Where Are We Going)?
It’s no secret that the FDA has recognized for years that the clinical trial system, with some of the worst return on investment (ROI) of any industry, is broken. Read…
Read More5 Bad Habits The Clinical Trial Community Needs To Break ASAP
The issue of clinical trial costs, both in terms of money and time, is big, complicated, and not at all new. The article discusses key persistent root causes and calls to…
Read MoreEvaluating Time In Range Potential in Reducing Costs of Diabetes Care
Estimated 30.3 million Americans, or 9.4% of the US population has diabetes, with the healthcare costs reaching nearly $404 billion annually (The economic burden of elevated blood glucose Level in 2017: diagnosed and…
Read MorePrecision Pathology as Part of Precision Medicine: Are We Optimizing Patients’ Interests in Prioritizing Use of Limited Tissue Samples?
Insufficient sample tissue and conflicting legal and regulatory requirements increasingly pose a practical obstacle for the implementation of precision medicine testing for patient treatment protocols and clinical trial research. While…
Read MoreComplex Innovative Trial Designs Pilot Program
FDA announces a set of presentations and a pilot program to advance Complex Innovative Clinical Trial Designs (CIDs) as a part of PDUFA VI (Aug 2017). The initiative is aimed…
Read MoreAI Applications in the Pharma Industry
A captivating debate is unfolding regarding applications of AI in pharma. In his book, AI Superpowers, and recent appearance on CBS 60 Minutes, Kai Fu Lee inspiringly represents the vision…
Read More